Effect of a High-Protein Diet With Meal Replacements on Weight Loss
Evaluation of the Effectiveness of a High-Protein Diet With Meal Replacement and Dietary Supplementation in a Weight Management Program
2 other identifiers
interventional
60
1 country
1
Brief Summary
The goal of this clinical trial is to learn if a structured high-protein diet with meal replacements can help with weight loss in adults with overweight or obesity. The main questions it aims to answer are: Does this diet help participants lose more body weight? Does this diet improve body composition and blood markers such as glucose and cholesterol? Researchers will compare a structured diet program with meal replacements to a standard low-calorie diet to see if it leads to better weight loss and health outcomes. Participants will: Follow a calorie-restricted diet for the duration of the study Be assigned to either a meal replacement program or a standard diet Attend study visits for body measurements and blood tests Report their feelings of hunger and fullness
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2026
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2026
CompletedFirst Submitted
Initial submission to the registry
April 17, 2026
CompletedFirst Posted
Study publicly available on registry
April 23, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
May 6, 2026
April 1, 2026
3 months
April 17, 2026
April 29, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in body weight (kg)
Change in body weight measured in kilograms. Body weight will be assessed at baseline and monthly during the study
Baseline to 3 months
Secondary Outcomes (9)
Change in body fat percentage (%)
Baseline to 3 months
Change in lean body mass (kg)
Baseline to 3 months
Change in body mass index (BMI, kg/m²)
Baseline to 3 months
Change in blood glucose concentration (mmol/L)
Baseline to 3 months
Change in total cholesterol (mmol/L)
Baseline to 3 months
- +4 more secondary outcomes
Study Arms (2)
High-Protein Diet with Meal Replacements
EXPERIMENTALParticipants follow a structured, calorie-restricted, high-protein diet that includes replacing two main meals per day with a protein-based meal replacement shake and taking additional dietary supplements in capsule form twice daily with snacks. Participants also receive individualized meal plans tailored to their caloric needs.
Standard Low-Calorie Diet
ACTIVE COMPARATORParticipants follow a standard calorie-restricted diet based on general nutritional recommendations without meal replacement products. Participants also receive individualized meal plans tailored to their caloric needs.
Interventions
Participants replace two main meals per day with a protein-based meal replacement shake and take additional dietary supplements in capsule form twice daily with snacks as part of a structured, calorie-restricted diet. Participants also follow individualized meal plans tailored to their caloric needs.
Participants follow a standard calorie-restricted diet based on general nutritional recommendations without meal replacement products or additional dietary supplements. Participants also follow individualized meal plans tailored to their caloric needs.
Eligibility Criteria
You may qualify if:
- Adults aged 25 to 60 years
- Overweight or obesity
- Ability to provide informed consent
- Willingness to follow a calorie-restricted diet program
- Willingness to comply with study procedures
You may not qualify if:
- Pregnancy or breastfeeding
- Women of reproductive potential who are not using reliable contraception during the study
- Severe or uncontrolled cardiovascular disease, including recent myocardial infarction or stroke within the past 6 months, unstable angina, or heart failure
- Uncontrolled arterial hypertension at screening
- Severe renal impairment
- Severe hepatic dysfunction
- Diabetes requiring insulin therapy or uncontrolled diabetes
- Active oncological disease or cancer treatment within the past 12 months
- Acute or chronic inflammatory disease in the acute stage
- History of gastrointestinal or bariatric surgery affecting absorption or body weight within the past 12 months
- Severe pulmonary disease in the stage of decompensation Allergy or intolerance to components of the study products, including milk proteins or lactose-containing products Current use of medications or dietary supplements that significantly affect body weight, if discontinuation before study start is not possible Participation in another interventional clinical study within the past 3 months Inability to provide informed consent or comply with the study protocol Significant body weight change, defined as more than 5% gain or loss, within the past 3 months before screening Severe psychiatric disorders or eating disorders that may interfere with participation Active alcohol or substance dependence Chronic use of systemic glucocorticoids or other medications affecting body weight, if discontinuation is not appropriate Planned pregnancy during the study period Uncontrolled thyroid disease Acute infection or febrile illness at screening Clinically significant abnormal laboratory findings at screening that, in the investigator's opinion, make participation unsafe
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Kazakh Academy of Nutrition LLP
Almaty, 050010, Kazakhstan
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Aliya Kaldybai
Kazakh Academy of Nutrition, Almaty, Kazakhstan
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- This is an open-label study. Both participants and researchers are aware of group assignments.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 17, 2026
First Posted
April 23, 2026
Study Start
April 1, 2026
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
July 1, 2026
Last Updated
May 6, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) will not be shared due to privacy and confidentiality considerations and the absence of a predefined data sharing plan.